RecruitingPhase 1NCT05636514
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Studying Acute myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Clinical Hub for Interventional Research (CHOIR)
- Principal Investigator
- John Pimanda, ProfessorUniversity of New South Wales
- Intervention
- Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (5)
- Prince of Wales Hospital, Sydney, New South Wales, Australia
- Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- Concord Repatriation and General Hospital, Sydney, New South Wales, Australia
- Nepean Hospital, Sydney, New South Wales, Australia
- Westmead Hospital, Westmead, New South Wales, Australia
Collaborators
The University of New South Wales · Australian National University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05636514 on ClinicalTrials.govOther trials for Acute myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06994676A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasCrossbow Therapeutics, Inc.
- RECRUITINGPHASE2NCT06680661ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisLeland Metheny
- RECRUITINGPHASE2NCT06778187Oral-ATO for TP53-mutated Myeloid MalignanciesThe University of Hong Kong
- RECRUITINGPHASE1NCT06247787A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyChildren's Oncology Group
- RECRUITINGNCT06111612Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT05807932Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE1, PHASE2NCT05092451Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05233618Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)Karen Ballen, MD